CTOs on the Move

TransCode Therapeutics

www.transcodetherapeutics.com

 
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Zdravka Medarova
 Chief Technology Officer Profile

Similar Companies

Jeiven Pharmaceutical Consulting

Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dsr Pharmaceuticals

Dsr Pharmaceuticals is a Playa Del Rey, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Janssen Alzheimer Immunotherapy div JNJ

Janssen Alzheimer Immunotherapy div JNJ is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroLift

The UroLift System is an FDA Cleared, revolutionary minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.